Radiochemotherapy in Anal Cancer: cCR, clinical outcomes and quality of life using two different treatment schedules.

Autor:	Di Santo S; Department of Radiotherapy, 'S.S. Annunziata' Hospital, 'G. D'Annunzio' University, via dei Vestini, 66100 Chieti, Italy., Trignani M; Department of Radiotherapy, 'S.S. Annunziata' Hospital, 'G. D'Annunzio' University, via dei Vestini, 66100 Chieti, Italy., Neri M; Department of Gastroenterology, 'S.S. Annunziata' Hospital, 'G. D'Annunzio' University, via dei Vestini, 66100 Chieti, Italy., Milano A; Department of Gastroenterology, 'S.S. Annunziata' Hospital, 'G. D'Annunzio' University, via dei Vestini, 66100 Chieti, Italy., Innocenti P; Department of Surgery, 'S.S. Annunziata' Hospital, 'G. D'Annunzio' University, via dei Vestini, 66100 Chieti, Italy., Taraborrelli M; Department of Radiotherapy, 'S.S. Annunziata' Hospital, 'G. D'Annunzio' University, via dei Vestini, 66100 Chieti, Italy., Augurio A; Department of Radiotherapy, 'S.S. Annunziata' Hospital, 'G. D'Annunzio' University, via dei Vestini, 66100 Chieti, Italy., Vinciguerra A; Department of Radiotherapy, 'S.S. Annunziata' Hospital, 'G. D'Annunzio' University, via dei Vestini, 66100 Chieti, Italy., Di Tommaso M; Department of Radiotherapy, 'S.S. Annunziata' Hospital, 'G. D'Annunzio' University, via dei Vestini, 66100 Chieti, Italy., Ursini LA; Department of Radiotherapy, 'S.S. Annunziata' Hospital, 'G. D'Annunzio' University, via dei Vestini, 66100 Chieti, Italy., Di Pilla A; Department of Radiotherapy, 'S.S. Annunziata' Hospital, 'G. D'Annunzio' University, via dei Vestini, 66100 Chieti, Italy., Di Nicola M; Laboratory of Biostatistics, Department of Biomedical Science, 'G. D'Annunzio' University, via dei Vestini, 66100 Chieti, Italy., Genovesi D; Department of Radiotherapy, 'S.S. Annunziata' Hospital, 'G. D'Annunzio' University, via dei Vestini, 66100 Chieti, Italy.
Jazyk:	angličtina
Zdroj:	Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology [Rep Pract Oncol Radiother] 2014 Nov 22; Vol. 20 (2), pp. 128-34. Date of Electronic Publication: 2014 Nov 22 (Print Publication: 2015).
DOI:	10.1016/j.rpor.2014.11.001
Abstrakt:	Aim: Main endpoint was a response rate to therapy; secondary endpoints were disease-free survival, overall survival, acute and late toxicities, specially in terms of anorectal and urinary continence. Background: Radiochemotherapy for anal cancer achieves a good clinical response, locoregional control, anal function preservation. However, oncologic outcomes can differ using radiotherapy plus fluorouracil and mytomicin vs. cisplatin and fluorouracil. Methods: Between 2000 and 2012, 27 anal cancer patients receiving radiotherapy combined with two different radiochemotherapy schedules, fluorouracil and mytomicin (group A) and cisplatin plus fluorouracil (group B). The Kaplan-Meier method was also used to estimate local control, overall survival and disease free survival. Statistical significance between curves was evaluated using the Log-rank test. Results: Complete pathological response was found in 85.2% of patients, with higher rates of response in the group A (100% vs. 63.6%, p = 0.039). No significantly difference was found between the two groups for the other endpoints. Low rates of both acute and late toxicities were recorded. Conclusion: Radiotherapy plus fluorouracil and mytomicin provide a better complete pathological response than radiotherapy plus cisplatin and fluorouracil and a greater rate of anal sphincter function preservation. Globally, radiochemotherapy of the anal cancer provides excellent clinical outcomes with a good profile of acute and late toxicity, without difference between the two groups studied.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu